Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONi-3 first-line metastatic non-small cell lung cancer study
2024-513087-26-00Phase 3Authorised
- Sponsor
- Summit Therapeutics
- Start
- Sep 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of ivonescimab, pembrolizumab, carboplatin, pemetrexed, paclitaxel and 1 more in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Summit Therapeutics. Primary endpoints: Overall survival and Progression-free survival by independent review. Planned start Sep 2024; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-513087-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513087-26-00.